Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients

References

• Scientific Registry of Transplant Recipients. Annual data report (2003-2015) [cited 2020 Mar 3]. Available from: https://srtr.transplant.hrsa.gov/archives.aspx
   Google Scholar
• Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2015 Annual data report: kidney. Am J Transplant. 2017 Jan;17(Suppl 1):21–116.
   PubMed Web of Science ®Google Scholar
• North American Pediatric Renal Trials and Collaborative Studies. Annual Transplant Report: North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). 2014 [cited Jun 2020]. Available from: https://web.emmes.com/study/ped/annlrept/annlrept.html
   Google Scholar
• Bezinover D, Saner F. Organ transplantation in the modern era. BMC Anesthesiol. 2019 Mar 4;19(1):32.
   PubMedGoogle Scholar
• US Food and Drug Administration. Drug Databases 2020 [2020 Mar 5]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/
   Google Scholar
• Wiseman AC. Induction therapy in renal transplantation: why? What agent? What dose? We may never know. Clin J Am Soc Nephrol. 2015 Jun 5;10(6):923–925.
   PubMed Web of Science ®Google Scholar
• Hellemans R, Bosmans JL, Abramowicz D. Induction therapy for kidney transplant recipients: do we still need Anti-IL2 receptor monoclonal antibodies? Am J Transplant. 2017 Jan;17(1):22–27.
   PubMed Web of Science ®Google Scholar
• Hart A, Lentine KL, Smith JM, et al. OPTN/SRTR 2019 Annual data report: kidney. Am J Transplant. 2021 Feb;21(Suppl 2):21–137.
   PubMedGoogle Scholar
• Shemshadi M, Hoseini R, Zareh R, et al. Use of Basiliximab with the standard immunosuppressive protocol in pediatric renal transplantation: a double-blind randomized clinical trial. Int J Organ Transplant Med. 2020;11(1):8–14.
   PubMed Web of Science ®Google Scholar
• Pape L. State-of-the-art immunosuppression protocols for pediatric renal transplant recipients. Pediatr Nephrol. 2019 Feb;34(2):187–194.
   PubMed Web of Science ®Google Scholar
• Josephson MA. Monitoring and managing graft health in the kidney transplant recipient. Clin J Am Soc Nephrol. 2011 Jul;6(7):1774–1780.
   PubMed Web of Science ®Google Scholar
• Oates A, Ahuja S, Lee MM, et al. Pediatric renal transplant biopsy with ultrasound guidance: the ‘core’ essentials. Pediatr Radiol. 2017 Nov;47(12):1572–1579.
   PubMed Web of Science ®Google Scholar
• Bunchman TE, Fryd DS, Sibley RK, et al. Manifestations of renal allograft rejection in small children receiving adult kidneys. Pediatr Nephrol. 1990 May;4(3):255–258.
   PubMed Web of Science ®Google Scholar
• Mitsnefes MM. Cardiovascular complications of pediatric chronic kidney disease. Pediatr Nephrol. 2008 Jan;23(1):27–39.
   PubMed Web of Science ®Google Scholar
• Lo A. Immunosuppression and metabolic syndrome in renal transplant recipients. Metab Syndr Relat Disord. 2004;2(4):263–273.
   PubMed Web of Science ®Google Scholar
• Wilson AC, Greenbaum LA, Barletta GM, et al. High prevalence of the metabolic syndrome and associated left ventricular hypertrophy in pediatric renal transplant recipients. Pediatr Transplant. 2010 Feb;14(1):52–60.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Brewer HB Jr., Cleeman JI, et al. Definition of metabolic syndrome: report of the national heart, lung, and blood Institute/American heart association conference on scientific issues related to definition. Circulation. 2004 Jan 27;109(3):433–438.
   PubMed Web of Science ®Google Scholar
• Shapiro R, Nalesnik M, McCauley J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation. 1999 Dec 27;68(12):1851–1854.
   PubMed Web of Science ®Google Scholar
• Hyun H, Park E, Cho M, et al. Post-Transplant lymphoproliferative diseases in pediatric kidney allograft recipients with Epstein-Barr virus viremia. J Korean Med Sci. 2019 Aug 5;34(30):e203.
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013 Aug 27;96(4):333–360.
   PubMed Web of Science ®Google Scholar
• Kranz B, Vester U, Wingen AM, et al. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplant. 2008 Jun;12(4):474–478.
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018 Jun;102(6):900–931.
   PubMed Web of Science ®Google Scholar
• Smith JM, Dharnidharka VR. Viral surveillance and subclinical viral infection in pediatric kidney transplantation. Pediatr Nephrol. 2015 May;30(5):741–748.
   PubMed Web of Science ®Google Scholar
• Malluche HH, Monier-Faugere MC, Herberth J. Bone disease after renal transplantation. Nat Rev Nephrol. 2010 Jan;6(1):32–40.
   PubMed Web of Science ®Google Scholar
• Bacchetta J, Ranchin B, Demede D, et al. The consequences of pediatric renal transplantation on bone metabolism and growth. Curr Opin Organ Transplant. 2013 Oct;18(5):555–562.
   PubMed Web of Science ®Google Scholar
• Ghanem ME, Emam ME, Albaghdady LA, et al. Effect of childhood kidney transplantation on puberty. Fertil Steril. 2010 Nov;94(6):2248–2252.
   PubMed Web of Science ®Google Scholar
• Ingelfinger JR, Grupe WE, Harmon WE, et al. Growth acceleration following renal-transplantation in children less than 7 Years of age. Pediatrics. 1981;68(2):255–259.
   PubMed Web of Science ®Google Scholar
• Grushkin CM, Fine RN. Growth in children following renal transplantation. Am J Dis Child. 1973 Apr;125(4):514–516.
   PubMedGoogle Scholar
• Harambat J, Cochat P. Growth after renal transplantation. Pediatr Nephrol. 2009 Jul;24(7):1297–1306.
   PubMed Web of Science ®Google Scholar
• Allen DB. Growth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am. 1996 Sep;25(3):699–717.
   PubMed Web of Science ®Google Scholar
• Peterson RE, Perens GS, Alejos JC, et al. Growth and weight gain of prepubertal children after cardiac transplantation. Pediatr Transplant. 2008 Jun;12(4):436–441.
   PubMed Web of Science ®Google Scholar
• Lopez-Espinosa JA, Yeste-Fernandez D, Iglesias-Berengue J, et al. Factors affecting catch-up growth after liver transplantation. J Pediatr Endocrinol Metab. 2004 Aug;17(8):1097–1103.
   PubMed Web of Science ®Google Scholar
• Sarwal MM, Vidhun JR, Alexander SR, et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation. 2003 Nov 15;76(9):1331–1339.
   PubMed Web of Science ®Google Scholar
• Silverstein DM, Aviles DH, LeBlanc PM, et al. Results of one-year follow-up of steroid-free immunosuppression in pediatric renal transplant patients. Pediatr Transplant. 2005 Oct;9(5):589–597.
   PubMed Web of Science ®Google Scholar
• Oberholzer J, John E, Lumpaopong A, et al. Early discontinuation of steroids is safe and effective in pediatric kidney transplant recipients. Pediatr Transplant. 2005 Aug;9(4):456–463.
   PubMed Web of Science ®Google Scholar
• Bhakta N, Marik J, Malekzadeh M, et al. Can pediatric steroid-free renal transplantation improve growth and metabolic complications? Pediatr Transplant. 2008 Dec;12(8):854–861.
   PubMed Web of Science ®Google Scholar
• Hocker B, John U, Plank C, et al. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years. Transplantation. 2004 Jul 27;78(2):228–234.
   PubMed Web of Science ®Google Scholar
• Delucchi A, Valenzuela M, Ferrario M, et al. Early steroid withdrawal in pediatric renal transplant on newer immunosuppressive drugs [Controlled Clinical Trial]. Pediatr Transplant. 2007 Nov;11(7):743–748.
   PubMed Web of Science ®Google Scholar
• Hamiwka LA, Burns A, Bell L. Prednisone withdrawal in pediatric kidney transplant recipients on tacrolimus-based immunosuppression: four-year data. Pediatr Transplant. 2006 May;10(3):337–344.
   PubMed Web of Science ®Google Scholar
• Motoyama O, Hasegawa A, Ohara T, et al. A prospective trial of steroid withdrawal after renal transplantation treated with cyclosporine and mizoribine in children: results obtained between 1990 and 2003 [Multicenter Study]. Pediatr Transplant. 2005 Apr;9(2):232–238.
   PubMed Web of Science ®Google Scholar
• Hocker B, Weber LT, Feneberg R, et al. Prospective, randomized trial on late steroid withdrawal in pediatric renal transplant recipients under cyclosporine microemulsion and mycophenolate mofetil. Transplantation. 2009 Mar 27;87(6):934–941.
   PubMed Web of Science ®Google Scholar
• Grenda R, Watson A, Trompeter R, et al. A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. Am J Transplant. 2010 Apr;10(4):828–836.
   PubMed Web of Science ®Google Scholar
• Leeaphorn N, Garg N, Khankin EV, et al. Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens: a retrospective analysis of the UNOS/OPTN database. Transpl Int. 2018 Feb;31(2):175–186.
   PubMed Web of Science ®Google Scholar
• De Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999 Dec;37(6):485–505.
   PubMed Web of Science ®Google Scholar
• Ferraresso M, Turolo S, Belingheri M, et al. Relationship between mRNA expression levels of CYP3A4, CYP3A5 and SXR in peripheral mononuclear blood cells and aging in young kidney transplant recipients under tacrolimus treatment. Pharmacogenomics. 2015;16(5):483–491.
   PubMed Web of Science ®Google Scholar
• Dobbels F, Ruppar T, De Geest S, et al. Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: a systematic review. Pediatr Transplant. 2010 Aug;14(5):603–613.
   PubMed Web of Science ®Google Scholar
• Tran JQ, Othman AA, Mikulskis A, et al. Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis. Clin Pharmacol. 2016;8:9–13.
   PubMedGoogle Scholar
• Diao L, Hang Y, Othman AA, et al. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers and subjects with multiple sclerosis: analysis of Phase I-III clinical trials. Clin Pharmacokinet. 2016 Aug;55(8):943–955.
   PubMed Web of Science ®Google Scholar
• Othman AA, Tran JQ, Tang MT, et al. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. Clin Pharmacokinet. 2014 Oct;53(10):907–918.
   PubMed Web of Science ®Google Scholar
• Nagai T, Gotoh Y, Watarai Y, et al. Pharmacokinetics and pharmacodynamics of basiliximab in Japanese pediatric renal transplant patients. Int J Clin Pharmacol Ther. 2010 Mar;48(3):214–223.
   PubMed Web of Science ®Google Scholar
• Hocker B, Kovarik JM, Daniel V, et al. Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. Transplantation. 2008 Nov 15;86(9):1234–1240.
   PubMed Web of Science ®Google Scholar
• Deierhoi MH, Haug M 3rd. Review of select transplant subpopulations at high risk of failure from standard immunosuppressive therapy. Clin Transplant. 2000 Oct;14(5):439–448.
   PubMed Web of Science ®Google Scholar
• Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet. 1986 Mar-Apr;11(2):107–132.
   PubMedGoogle Scholar
• US Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products: U.S. department of health and human services; [Jun 2020]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/
   Google Scholar
• Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet. 2001;40(8):573–585.
   PubMed Web of Science ®Google Scholar
• Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623–653.
   PubMed Web of Science ®Google Scholar
• Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13–58.
   PubMed Web of Science ®Google Scholar
• Miura M, Satoh S, Inoue K, et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161–1169.
   PubMed Web of Science ®Google Scholar
• Sherwin CM, Fukuda T, Brunner HI, et al. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1–24.
   PubMed Web of Science ®Google Scholar
• Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995 Jul;41(7):1011–1017.
   PubMed Web of Science ®Google Scholar
• Yatscoff R, LeGatt D, Keenan R, et al. Blood distribution of rapamycin. Transplantation. 1993 Nov;56(5):1202–1206.
   PubMed Web of Science ®Google Scholar
• Piekoszewski W, Jusko WJ. Plasma protein binding of tacrolimus in humans. J Pharm Sci. 1993 Mar;82(3):340–341.
   PubMed Web of Science ®Google Scholar
• Lemaire M, Tillement JP. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol. 1982 Nov;34(11):715–718.
   PubMed Web of Science ®Google Scholar
• Hoogeveen RC, Ballantyne CM, Pownall HJ, et al. Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. Transplantation. 2001 Oct 15;72(7):1244–1250.
   PubMed Web of Science ®Google Scholar
• Ferron GM, Mishina EV, Zimmerman JJ, et al. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther. 1997 Apr;61(4):416–428.
   PubMed Web of Science ®Google Scholar
• Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther. 1995 Mar;57(3):281–290.
   PubMed Web of Science ®Google Scholar
• Langman LJ, LeGatt DF, Yatscoff RW. Blood distribution of mycophenolic acid. Ther Drug Monit. 1994 Dec;16(6):602–607.
   PubMed Web of Science ®Google Scholar
• Picard N, Rouguieg-Malki K, Kamar N, et al. CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. Transplantation. 2011 Mar 27;91(6):652–656.
   PubMed Web of Science ®Google Scholar
• Picard N, Ratanasavanh D, Premaud A, et al. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139–146.
   PubMed Web of Science ®Google Scholar
• Naesens M, Salvatierra O, Li L, et al. Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. Transplantation. 2008 Apr 27;85(8):1139–1145.
   PubMed Web of Science ®Google Scholar
• Schachter AD, Meyers KE, Spaneas LD, et al. Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. Pediatr Transplant. 2004 Apr;8(2):171–177.
   PubMed Web of Science ®Google Scholar
• Filler G, Foster J, Berard R, et al. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. Transplant Proc. 2004 Jun;36(5):1327–1331.
   PubMed Web of Science ®Google Scholar
• Fanta S, Jonsson S, Backman JT, et al. Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates. Br J Clin Pharmacol. 2007 Dec;64(6):772–784.
   PubMed Web of Science ®Google Scholar
• Job KM, Gamalo M, Ward RM. Pediatric age groups and approach to studies. Ther Innov Regul Sci. 2019 Sep;53(5):584–589.
   PubMed Web of Science ®Google Scholar
• Hines RN. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharm. 2013 Aug 16;452(1–2):3–7.
   PubMed Web of Science ®Google Scholar
• Lacroix D, Sonnier M, Moncion A, et al. Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem. 1997 Jul 15;247(2):625–634.
   PubMedGoogle Scholar
• Liu H, Xu Q, Huang W, et al. CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic range proteinuria. Eur J Clin Pharmacol. 2019 Nov;75(11):1533–1540.
   PubMed Web of Science ®Google Scholar
• De Wildt SN, van Schaik RH, Soldin OP, et al. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. Eur J Clin Pharmacol. 2011 Dec;67(12):1231–1241.
   PubMed Web of Science ®Google Scholar
• Zhao W, Fakhoury M, Jacqz-Aigrain E. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation. Ther Drug Monit. 2010 Dec;32(6):688–699.
   PubMed Web of Science ®Google Scholar
• Irtan S, Saint-Marcoux F, Rousseau A, et al. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients. Ther Drug Monit. 2007 Feb;29(1):96–102.
   PubMed Web of Science ®Google Scholar
• Andrews LM, Hesselink DA, van Gelder T, et al. A population pharmacokinetic model to predict the individual starting dose of tacrolimus following pediatric renal transplantation. Clin Pharmacokinet. 2018 Apr;57(4):475–489.
   PubMed Web of Science ®Google Scholar
• Le Guellec C, Bourgoin H, Buchler M, et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet. 2004;43(4):253–266.
   PubMed Web of Science ®Google Scholar
• Zhao W, Fakhoury M, Deschenes G, et al. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J Clin Pharmacol. 2010 Nov;50(11):1280–1291.
   PubMed Web of Science ®Google Scholar
• Payen S, Zhang D, Maisin A, et al. Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients. Ther Drug Monit. 2005 Jun;27(3):378–388.
   PubMed Web of Science ®Google Scholar
• Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000 May;47(2–3):119–125.
   PubMed Web of Science ®Google Scholar
• Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S40–5.
   PubMedGoogle Scholar
• Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998 Jun;34(6):429–455.
   PubMed Web of Science ®Google Scholar
• Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003 May;35(3Suppl):7S–14S.
   PubMed Web of Science ®Google Scholar
• Kahan BD, Gibbons S, Tejpal N, et al. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation. 1991 Jan;51(1):232–239.
   PubMed Web of Science ®Google Scholar
• McAlister VC, Gao Z, Peltekian K, et al. Sirolimus-tacrolimus combination immunosuppression. Lancet. 2000 Jan 29;355(9201):376–377.
   PubMed Web of Science ®Google Scholar
• Gauthier P, Helderman JH. Cyclosporine avoidance. J Am Soc Nephrol. 2000 Oct;11(10):1933–1936.
   PubMed Web of Science ®Google Scholar
• Lorber MI, Van Buren CT, Flechner SM, et al. Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. Transplantation. 1987 Jan;43(1):35–40.
   PubMed Web of Science ®Google Scholar
• Jacobson PA, Schladt D, Israni A, et al. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium. Transplantation. 2012 Mar 27;93(6):624–631.
   PubMed Web of Science ®Google Scholar
• Lancia P, Adam De Beaumais T, Elie V, et al. Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus. Pediatr Nephrol. 2018 Jun;33(6):1045–1055.
   PubMed Web of Science ®Google Scholar
• Shivaswamy V, Boerner B, Larsen J. Post-Transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev. 2016 Feb;37(1):37–61.
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000 May;47(2–3):85–118.
   PubMed Web of Science ®Google Scholar
• Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf. 2001;24(9):645–663.
   PubMed Web of Science ®Google Scholar
• Downing HJ, Pirmohamed M, Beresford MW, et al. Paediatric use of mycophenolate mofetil. Br J Clin Pharmacol. 2013 Jan;75(1):45–59.
   PubMed Web of Science ®Google Scholar
• Wyeth Pharmaceuticals Inc. Drug label: highlighs of prescribing information: rapamune (Sirolimus) oral solution and tablets: US FDA; 2010 [ updated 09/2010; cited Jun 2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021110s058lbl.pdf
   Google Scholar
• Merkel S, Mogilevskaja N, Mengel M, et al. Side effects of sirolimus. Transplant Proc. 2006 Apr;38(3):714–715.
   PubMed Web of Science ®Google Scholar
• Habbig S, Volland R, Krupka K, et al. Dyslipidemia after pediatric renal transplantation-The impact of immunosuppressive regimens. Pediatr Transplant. 2017 May;21(3):3.
   Web of Science ®Google Scholar
• Bock ME, Wall L, Dobrec C, et al. Management of dyslipidemia in pediatric renal transplant recipients. Pediatr Nephrol. 2021 Jan;36(1):51–63.
   PubMed Web of Science ®Google Scholar
• Seeman T. Immunosuppressive management of pediatric kidney transplant recipients. Curr Pharm Des. 2020;26(28):3451–3459.
   PubMed Web of Science ®Google Scholar
• Hricik DE, Augustine J, Nickerson P, et al. Interferon gamma ELISPOT testing as a Risk-Stratifying biomarker for kidney transplant injury: results from the CTOT-01 multicenter study. Am J Transplant. 2015 Dec;15(12):3166–3173.
   PubMed Web of Science ®Google Scholar
• Billing H, Giese T, Sommerer C, et al. Pharmacodynamic monitoring of cyclosporine A by NFAT-regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients. Pediatr Transplant. 2010 Nov;14(7):844–851.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Chandar JJ, Rusconi PG, et al. Issues in solid-organ transplantation in children: translational research from bench to bedside. Clinics (Sao Paulo). 2014;69(Suppl1):55–72.
   PubMedGoogle Scholar
• Hooper E, Hawkins DM, Kowalski RJ, et al. Establishing pediatric immune response zones using the Cylex ImmuKnow assay. Clin Transplant. 2005 Dec;19(6):834–839.
   PubMed Web of Science ®Google Scholar
• Vyas S, Roberti I. Lymphocyte ATP immune cell function assay in pediatric renal transplants: is it useful? Transplant Proc. 2011 Dec;43(10):3675–3678.
   PubMed Web of Science ®Google Scholar
• Fukuda T, Goebel J, Thogersen H, et al. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. J Clin Pharmacol. 2011 Mar;51(3):309–320.
   PubMed Web of Science ®Google Scholar
• Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant. 2003 May;3(5):534–542.
   PubMed Web of Science ®Google Scholar
• Yu M, Liu M, Zhang W, et al. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Curr Drug Metab. 2018;19(6):513–522.
   PubMed Web of Science ®Google Scholar
• Hesselink DA, Bouamar R, Elens L, et al. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2014 Feb;53(2):123–139.
   PubMed Web of Science ®Google Scholar
• Woillard J-B, Saint-Marcoux F, Monchaud C, et al. Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients. Pharmacol Res. 2015 Sep;99:308–315.
   PubMed Web of Science ®Google Scholar
• Thervet E. [Recents advances in the pharmacology of immunosuppressive drugs used in organ transplantation]. Med Sci (Paris). 2008 Nov;24(11):961–966.
   PubMed Web of Science ®Google Scholar
• Ferraresso M, Belingheri M, Turolo S, et al. Long-term effects of ABCB1 and SXR SNPs on the systemic exposure to cyclosporine in pediatric kidney transplant patients. Pharmacogenomics. 2013 Oct;14(13):1605–1613.
   PubMed Web of Science ®Google Scholar
• Fanta S, Niemi M, Jonsson S, et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics. 2008 Feb;18(2):77–90.
   PubMed Web of Science ®Google Scholar
• Ferraresso M, Turolo S, Belinghieri M, et al. The potential of steroids and xenobiotic receptor polymorphisms in forecasting cyclosporine pharmacokinetic variability in young kidney transplant recipients. Pediatr Transplant. 2012 Sep;16(6):658–663.
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Drocourt L, Fabre JM, et al. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol. 2000 Aug;58(2):361–372.
   PubMed Web of Science ®Google Scholar
• Roy JN, Barama A, Poirier C, et al. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics. 2006 Sep;16(9):659–665.
   PubMed Web of Science ®Google Scholar
• Mourad M, Wallemacq P, De Meyer M, et al. The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function. Clin Chem Lab Med. 2006;44(10):1192–1198.
   PubMed Web of Science ®Google Scholar
• Tang JT, Andrews LM, van Gelder T, et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Expert Opin Drug Metab Toxicol. 2016 May;12(5):555–565.
   PubMed Web of Science ®Google Scholar
• Almeida-Paulo GN, Dapia Garcia I, Lubomirov R, et al. Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant. Pharmacogenomics J. 2018 Jan;18(1):180–186.
   PubMed Web of Science ®Google Scholar
• Zhao W, Elie V, Roussey G, et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009 Dec;86(6):609–618.
   PubMed Web of Science ®Google Scholar
• Shilbayeh S. The impact of genetic polymorphisms on time required to attain the target tacrolimus levels and subsequent pharmacodynamic outcomes in pediatric kidney transplant patients. Saudi J Kidney Dis Transpl. 2014 Mar;25(2):266–277.
   PubMedGoogle Scholar
• Prausa SE, Fukuda T, Maseck D, et al. UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009 May;85(5):495–500.
   PubMed Web of Science ®Google Scholar
• Fukuda T, Goebel J, Cox S, et al. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients. Ther Drug Monit. 2012 Dec;34(6):671–679.
   PubMed Web of Science ®Google Scholar
• Woillard JB, Picard N, Thierry A, et al. Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. Pharmacogenet Genomics. 2014 May;24(5):256–262.
   PubMed Web of Science ®Google Scholar
• Jacobson PA, Schladt D, Oetting WS, et al. Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation. Transplantation. 2011 Feb 15;91(3):309–316.
   PubMed Web of Science ®Google Scholar
• Anglicheau D, Le Corre D, Lechaton S, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant. 2005 Mar;5(3):595–603.
   PubMed Web of Science ®Google Scholar
• Le Meur Y, Djebli N, Szelag JC, et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther. 2006 Jul;80(1):51–60.
   PubMed Web of Science ®Google Scholar
• Emoto C, Fukuda T, Venkatasubramanian R, et al. The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model. Br J Clin Pharmacol. 2015 Dec;80(6):1438–1446.
   PubMed Web of Science ®Google Scholar
• Dirks NL, Huth B, Yates CR, et al. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther. 2004 Dec;42(12):701–718.
   PubMed Web of Science ®Google Scholar
• Taber DJ, Su Z, Fleming JN, et al. Tacrolimus trough concentration variability and disparities in african american kidney transplantation. Transplantation. 2017 Dec;101(12):2931–2938.
   PubMed Web of Science ®Google Scholar
• Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics. 2004 Apr;5(3):243–272.
   PubMed Web of Science ®Google Scholar
• Thervet E, Anglicheau D, Legendre C, et al. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit. 2008 Apr;30(2):143–150.
   PubMed Web of Science ®Google Scholar
• Pallet N, Thervet E, Alberti C, et al. Kidney transplant in black recipients: are African Europeans different from African Americans? Am J Transplant. 2005 Nov;5(11):2682–2687.
   PubMed Web of Science ®Google Scholar
• Thervet E, Anglicheau D, King B, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation. 2003 Oct 27;76(8):1233–1235.
   PubMed Web of Science ®Google Scholar
• Li CJ, Li L. Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use. Drug Des Devel Ther. 2015;9:473–485.
   PubMed Web of Science ®Google Scholar
• Li P, Shuker N, Hesselink DA, et al. Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients? Transpl Int. 2014 Oct;27(10):994–1004.
   PubMed Web of Science ®Google Scholar
• Friedman AL, Geoghegan SR, Sowers NM, et al. Medication errors in the outpatient setting: classification and root cause analysis. Arch Surg. 2007 Mar;142(3):278–283. discussion 284.
   PubMed Web of Science ®Google Scholar
• Katz DT, Torres NS, Chatani B, et al. Care of pediatric solid organ transplant recipients: an overview for primary care providers. Pediatrics. 2020 Dec;146(6):6.
   Web of Science ®Google Scholar
• Weber LT. Therapeutic drug monitoring in pediatric renal transplantation. Pediatr Nephrol. 2015 Feb;30(2):253–265.
   PubMed Web of Science ®Google Scholar
• Jaklic A, Collins CJ, Mrhar A, et al. High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients. Int J Clin Pharmacol Ther. 2013 Sep;51(9):711–717.
   PubMed Web of Science ®Google Scholar
• Shaw LM, Figurski M, Milone MC, et al. Therapeutic drug monitoring of mycophenolic acid. Clin J Am Soc Nephrol. 2007 Sep;2(5):1062–1072.
   PubMed Web of Science ®Google Scholar
• Foy M, Sperati CJ, Lucas GM, et al. Drug interactions and antiretroviral drug monitoring. Curr HIV/AIDS Rep. 2014 Sep;11(3):212–222.
   PubMed Web of Science ®Google Scholar
• Filler G. Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation. Pediatr Transplant. 2006 Sep;10(6):707–711.
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Ekberg H, Grinyo J, et al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clin Pharmacokinet. 2009;48(5):329–341.
   PubMed Web of Science ®Google Scholar
• Hocker B, van Gelder T, Martin-Govantes J, et al. Comparison of MMF efficacy and safety in paediatric vs. adult renal transplantation: subgroup analysis of the randomised, multicentre FDCC trial. Nephrol Dial Transplant. 2011 Mar;26(3):1073–1079.
   PubMed Web of Science ®Google Scholar
• Weber LT, Hoecker B, Armstrong VW, et al. Long-term pharmacokinetics of mycophenolic acid in pediatric renal transplant recipients over 3 years posttransplant. Ther Drug Monit. 2008 Oct;30(5):570–575.
   PubMed Web of Science ®Google Scholar
• Schachter AD, Benfield MR, Wyatt RJ, et al. Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy. Pediatr Transplant. 2006 Dec;10(8):914–919.
   PubMed Web of Science ®Google Scholar
• Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation. 1998 Oct 27;66(8):1040–1046.
   PubMed Web of Science ®Google Scholar
• Zimmerman JJ, Harper D, Getsy J, et al. Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. J Clin Pharmacol. 2003 Oct;43(10):1168–1176.
   PubMed Web of Science ®Google Scholar
• Schubert M, Venkataramanan R, Holt DW, et al. Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. Am J Transplant. 2004 May;4(5):767–773.
   PubMed Web of Science ®Google Scholar
• Filler G, Womiloju T, Feber J, et al. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. Am J Transplant. 2005 Aug;5(8):2005–2010.
   PubMed Web of Science ®Google Scholar
• Trofe-Clark J, Lemonovich TL, Practice A. Interactions between anti-infective agents and immunosuppressants in solid organ transplantation. Am J Transplant. 2013 Mar;13(Suppl 4):318–326.
   PubMedGoogle Scholar
• Page RL 2nd, Mueller SW, Levi ME, et al. Pharmacokinetic drug-drug interactions between calcineurin inhibitors and proliferation signal inhibitors with anti-microbial agents: implications for therapeutic drug monitoring. J Heart Lung Transplant. 2011 Feb;30(2):124–135.
   PubMed Web of Science ®Google Scholar
• Urbanowicz T, Straburzynska-Migaj E, Casadei V, et al. Different routes of proton pumps inhibitors co-administration have significant impact on Mycophenolate Acid (MPA) serum levels in heart transplant recipients. Ann Transplant. 2020 Jan;24(25):e920225.
   Google Scholar
• Sunderland A, Russ G, Sallustio B, et al. Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial. Nephrol Dial Transplant. 2020 Jun 1;35(6):1060–1070.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002 Sep;62(3):1060–1067.
   PubMed Web of Science ®Google Scholar
• De Lucena DD, Rangel EB. Glucocorticoids use in kidney transplant setting. Expert Opin Drug Metab Toxicol. 2018 Oct;14(10):1023–1041.
   PubMed Web of Science ®Google Scholar
• Hooper DK, Fukuda T, Gardiner R, et al. Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. Transplantation. 2012 Apr 27;93(8):806–812.
   PubMed Web of Science ®Google Scholar
• Chow FS, Jusko WJ. Immunosuppressive interactions among calcium channel antagonists and selected corticosteroids and macrolides using human whole blood lymphocytes. Drug Metab Pharmacokinet. 2004 Dec;19(6):413–421.
   PubMedGoogle Scholar
• Uber PA, Ross HJ, Zuckermann AO, et al. Generic drug immunosuppression in thoracic transplantation: an ISHLT educational advisory. J Heart Lung Transplant. 2009 Jul;28(7):655–660.
   PubMed Web of Science ®Google Scholar
• Davit BM, Nwakama PE, Buehler GJ, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother. 2009 Oct;43(10):1583–1597.
   PubMed Web of Science ®Google Scholar
• Qazi YA, Forrest A, Tornatore K, et al. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function. Clin Transplant. 2006 May-Jun;20(3):313–317.
   PubMed Web of Science ®Google Scholar
• Abboudi H, Macphee IA. Individualized immunosuppression in transplant patients: potential role of pharmacogenetics. Pharmgenomics Pers Med. 2012;5:63–72.
   PubMedGoogle Scholar
• Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant. 2003 Nov;18(11):2409–2414.
   PubMed Web of Science ®Google Scholar
• Chen PD, Tsai MK, Lee CY, et al. Gender differences in renal transplant graft survival. J Formos Med Assoc. 2013 Dec;112(12):783–788.
   PubMed Web of Science ®Google Scholar
• Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol. 2000 Feb;14(2):100–104.
   PubMed Web of Science ®Google Scholar
• Krenzien F, ElKhal A, Quante M, et al. A rationale for age-adapted immunosuppression in organ transplantation. Transplantation. 2015 Nov;99(11):2258–2268.
   PubMed Web of Science ®Google Scholar
• Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Saf. 1997 Apr;16(4):267–278.
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med. 2003 Sep 18;349(12):1157–1167.
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Le Meur Y, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol. 2010 Feb;5(2):341–358.
   PubMed Web of Science ®Google Scholar
• Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German study group on mycophenolate mofetil therapy in pediatric renal transplant recipients. J Am Soc Nephrol. 1998 Aug;9(8):1511–1520.
   PubMed Web of Science ®Google Scholar
• Shipkova M, Armstrong VW, Oellerich M, et al. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol. 2005 Oct;1(3):505–526.
   PubMedGoogle Scholar
• Weber LT, Armstrong VW, Shipkova M, et al. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. Ther Drug Monit. 2004 Aug;26(4):415–424.
   PubMed Web of Science ®Google Scholar
• Lee MN, Butani L. Improved pharmacokinetic monitoring of tacrolimus exposure after pediatric renal transplantation. Pediatr Transplant. 2007 Jun;11(4):388–393.
   PubMed Web of Science ®Google Scholar
• Zhao W, Maisin A, Baudouin V, et al. Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children. Eur J Clin Pharmacol. 2013 May;69(5):1181–1185.
   PubMed Web of Science ®Google Scholar
• Filler G, Feber J, Lepage N, et al. Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant. 2002 Oct;6(5):411–418.
   PubMed Web of Science ®Google Scholar
• Ettenger RB, Grimm EM. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis. 2001 Oct;38(4 Suppl 2):S22–8.
   PubMed Web of Science ®Google Scholar
• Filler G. Optimization of immunosuppressive drug monitoring in children. Transplant Proc. 2007 May;39(4):1241–1243.
   PubMed Web of Science ®Google Scholar
• Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43(2):83–95.
   PubMed Web of Science ®Google Scholar
• Oellerich M, Armstrong VW, Streit F, et al. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Clin Biochem. 2004 Jun;37(6):424–428.
   PubMed Web of Science ®Google Scholar
• Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004 Dec 23;351(26):2715–2729.
   PubMed Web of Science ®Google Scholar
• Dipiro J, Talbert R, GC Y, et al. Pharmacotherapy: a pathophysiologic approach. 7 ed. New York, NYMcGraw-Hill Companies; 2008.
   Google Scholar
• United States Department of Health and Human Services. Transplants by donor type 2013 [cited Jun 2020]. Available from: http://optn.transplant.hrsa.gov/latestData/rptData.asp
   Google Scholar
• National Kidney Foundation. Organ donation and transplantation statistics 2016 [cited Jun 2020]. Available from: https://www.kidney.org/news/newsroom/factsheets/Organ-Donation-and-Transplantation-Stats
   Google Scholar
• Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther. 2002 Mar;24(3):330–350. discussion 329.
   PubMed Web of Science ®Google Scholar
• Buchler M, Johnston A. Seeking optimal prescription of cyclosporine ME. Ther Drug Monit. 2005 Feb;27(1):3–6.
   PubMed Web of Science ®Google Scholar
• Jorga A, Holt DW, Johnston A. Therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004 Mar;36(2 Suppl):396S–403S.
   PubMedGoogle Scholar
• Christians U, Strom T, Zhang YL, et al. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2006 Feb;28(1):39–44.
   PubMed Web of Science ®Google Scholar
• Sabatini S, Ferguson RM, Helderman JH, et al. Drug substitution in transplantation: a national kidney foundation white paper. Am J Kidney Dis. 1999 Feb;33(2):389–397.
   PubMed Web of Science ®Google Scholar
• Alloway RR, Isaacs R, Lake K, et al. Report of the American society of transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant. 2003 Oct;3(10):1211–1215.
   PubMed Web of Science ®Google Scholar
• Tsipotis E, Gupta NR, Raman G, et al. Bioavailability, efficacy and safety of generic immunosuppressive drugs for kidney transplantation: a systematic review and meta-analysis. Am J Nephrol. 2016;44(3):206–218.
   PubMed Web of Science ®Google Scholar
• El-tahtawy AA, Jackson AJ, Ludden TM. Comparison of single and multiple dose pharmacokinetics using clinical bioequivalence data and Monte Carlo simulations. Pharm Res. 1994 Sep;11(9):1330–1336.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations 2003 [cited Jun 2020]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf
   Google Scholar
• Phillips K, Reddy P, Gabardi S. Is there evidence to support brand to generic interchange of the mycophenolic acid products? J Pharm Pract. 2017 Feb;30(1):9–16.
   PubMedGoogle Scholar
• US Food and Drug Administration. Advisory committee for pharmaceutical science and clinical pharmacology 2010 [cited Jun 2020]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM212591.pdf
   Google Scholar
• Alloway RR, Vinks AA, Fukuda T, et al. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: a randomized, crossover clinical trial. PLoS Med. 2017 Nov;14(11):e1002428.
   PubMed Web of Science ®Google Scholar
• Illamola SM, Birnbaum AK, Sherwin CM. Generic drug products in paediatrics: where are the data? Br J Clin Pharmacol. 2019 Sep;85(9):1871–1873.
   PubMed Web of Science ®Google Scholar